There is a lot of macro "noise" in the market right now, as one Wall Street analyst called it, with higher tariffs, changes ...

Notably, the companys EBITDA surged by 16.5 percent, increasing from Rs 586.3 crore to Rs 683.2 crore from previous year.

The Wasatch Ultra Growth Fund—Investor Class underperformed the benchmark with a return of -14.81%. Read more here.

Antimicrobial-resistant (AMR) “superbugs” contribute to more than 4.5 million deaths globally per year and threaten to make ...

The president announced last week that his administration would be instituting a “most favored nation” policy that would peg ...

Dividend growth stocks have long been reliable engines of wealth creation. Historically, companies with 10-year annualized ...

People need healthcare products and services regardless of what's happening with the economy. Which healthcare stocks could ...

BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made ...

Trump’s executive order to cap U.S. costs risks limiting the supply of new pharmaceuticals. President Donald Trump’s ...

Fierce 15 nominations are open! We're searching for the most innovative, resourceful and visionary biotechs leading the way ...

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...